Diagnosis, Treatment and Prevention of Parkinson's Disease
Parkinson's disease is the second most common neurodegenerative disease after Alzheimer's disease, affecting between 1 and 3% of the population over the age of 65 in Western countries.
The main risk factors for developing Parkinson's disease are: (i) Age. (ii) Presence of a family history of the disease. (iii ) Continuous exposure to environmental neurotoxic agents, drugs, pesticides. (iv) Genomic defects in various genes distributed throughout the human genome. (v) Cerebral microinfarcts. (vi) Epigenetic changes (DNA methylation). (vii) Traumatic micro-injuries. (viii) Gender (affects more males) (ix) Other factors.
The medical and scientific team of the International Centre for Neuroscience and Genomic Medicine, led by Dr. Cacabelos, has developed a UNIQUE PROTOCOL for clinical action for the diagnosis, treatment and prevention of Parkinson's disease.
Diagnosis in a single session
We carry out all the tests required by each person (analytical, neuropsychological, etc.) in a single day to reach an accurate diagnosis.
Alzheimer's Prevention Plan
Programme for identifying the risk of Alzheimer's disease, or other forms of dementia, many years before the first symptoms appear. Allows discrimination of other memory disorders and dementias (vascular, mixed, fronto-temporal, Lewy body).
Alzheimer's disease has no curative treatment and current drugs (donepezil, rivastigmine, galantamine, memantine) are of limited efficacy in preserving memory and are not without toxicity. Work is underway on vaccines, but these will not be available for a decade, so the best form of intervention is considered to be preventive, intercepting the disease before it manifests itself through personalised intervention formulas.
MEDICAL EXAMINATION
LABORATORY ANALYSIS
IMAGING TESTS
DIGITAL DIAGNOSTIC TESTS
NEUROPSYCHOLOGICAL AND PSYCHOMETRIC ASSESSMENT
GENOMIC DIAGNOSIS
PHARMACOGENETIC PROFILE
EPIGENETIC BIOMARKERS
MEDICAL EXAMINATION
- General Examination
- Systemic Review
- Neurological Examination
- Psychiatric Examination
LABORATORY ANALYSIS
- Blood tests:
- Biochemistry
- Blood count
- Metabolism
- Hormones
- Analysis of urine and other body fluids
- Special tests:
- Neurotransmitters
- Tumour markers
- Customised Panels
- Food Intolerances
IMAGING TESTS
- Radiology
- Densitometry
- Magnetic Resonance Imaging
- Computerised Axial Tomography
DIGITAL DIAGNOSTIC TESTS
- Brain Mapping
- Digital Optical Surveying
- Ultrasonography
- Electrophysiology
- Specific Somatosensory Tests by Sense Organs (Vision, Hearing, Smell, Taste, Touch)
- Psychomotor tests
NEUROPSYCHOLOGICAL AND PSYCHOMETRIC ASSESSMENT
- Cognitive Function
- Emotional Status
- Conduct
- Intelligence
- Psychomotricity
GENOMIC DIAGNOSIS
- Global exome (NGS technology)
- Specific diagnostic panels:
- Predictive genomics
- Diagnostic Genomics
- Monogenic Genetic Analysis
PHARMACOGENETIC PROFILE
- Global Pharmacogenetic Profile (PGx-60/4000)
- Pharmacogenetic Profile by Pathology
- Pharmacogenetic Profile by Pharmacological Category
- Pharmacogenetic Profile by Drug
EPIGENETIC BIOMARKERS
- Global DNA methylation
- Expression of Pathogenic Genes
- Expression of FarmaGenes (PharmacoEpiGenetics)
WHAT OUR DIAGNOSTIC PROTOCOL CONSISTS OF
1. Clinical evaluation.
- Initial assessment of the patient.
- Complete medical examination.
2.- Tests to be carried out.
- Complete Blood Evaluation.
- Brain Evaluation:
- Morphological: MRI and CT.
- Functional: Topography, Brain Bioelectrical Activity and Transcranial Doppler.
- Full Body Evaluation: Digestive, Bone, Pulmonary Function, Vascular Examination (Arterial and Venous) and Genitourinary System.
- Cardiovascular evaluation.
- Neuropsychological evaluation.
- Genomic Tracing (*):
- Parkinson's Genetic Panel.
- Cerebrovascular Disease Genetic Panel.
- Epigenetic Biomarkers: Global Methylation.
- Pharmacogenetics. (Personalised treatment according to your genetics).
- Food Sensitivity Tests.
- Other tests to be determined at the initial medical assessment:
- Neuro - Otorhinolaryngology.
- Neuro - Ophthalmology.
These tests are available to be carried out in advance at your home. Please ask for information.
3. Analysis of the results obtained.
At the end of the testing day, we obtain a clinical diagnosis that allows us to carry out a personalised preventive and/or therapeutic intervention programme for each patient.
4.- Medical report.
Includes all the tests in the diagnostic process and the treatment guidelines to follow based on the patient's pharmacogenetic profile.
This programme is also aimed at:
1.- First and second-generation relatives with a history of Parkinson's disease in the family.
2.- People with cardiovascular and/or cerebrovascular diseases that represent risk factors for Parkinson's disease.
3.-People who have had mild, moderate or severe traumatic brain injuries as they are at increased risk of developing Parkinson's disease.
General population aged 30-35 years and older who want to know their genetic risk profile for Parkinson's disease.
ATREMORINE
MEET AtreMorine, a nutraceutical developed by EuroEspes Group researchers and manufactured at Ebiotec, the Group's biotechnology plant. AtreMorine is a natural bioproduct, specially designed for patients with Parkinson's disease and other parkinsonian syndromes.
E-PodoFavalin-15999 (AtreMorine®) is a novel biopharmaceutical compound obtained by non-denaturing biotechnological processes from structural components of the plant Vicia faba L.(natural source of L-dopa, a precursor of the neurotransmitter dopamine). This compound has demonstrated a neuroprotective effect on dopaminergic neurons in the substantia nigra pars compacta (brain region affected in PD) in animal models of PD.
Clinical studies indicate that AtreMorine® is a powerful dopamine and noradrenaline enhancer in Parkinsonian patients.
AtreMorine®is a good option to minimise the "wearing-off" phenomenon, prolonging the effect of conventional antiparkinsonian drugs at low doses, and, above all, to protect dopaminergic neurons against the process of premature death.
The powerful prodopaminergic effect of AtreMorine®, with a 200-300-fold increase in dopamine over baseline levels, is also regulated by pharmacogenetic factors, so that its therapeutic response depends on the pharmacogenetic profile of each patient. In addition to a high L-dopa content (between 20 and 25 mg/g of AtreMorine®), AtreMorine® also contains other biologically active compounds such as phytosterols and carotenoid pigments.